The Defense Health Agency awarded the University of Florida Division of Sponsored Research $1.499 million on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to enhance immunotherapy treatment response in triple-negative breast cancer through development of a novel molecular glue degrader of the COREST complex. Work is performed in Gainesville, Florida, with a period of performance extending through October 31, 2029.